NASDAQ:XENE Xenon Pharmaceuticals (XENE) Stock Price, News & Analysis $43.96 +0.11 (+0.25%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$43.45▼$44.4450-Day Range$36.12▼$43.9652-Week Range$27.99▼$50.99Volume275,291 shsAverage Volume457,226 shsMarket Capitalization$3.32 billionP/E RatioN/ADividend YieldN/APrice Target$59.11 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Xenon Pharmaceuticals alerts: Email Address Xenon Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside34.5% Upside$59.11 Price TargetShort InterestBearish4.33% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.48Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.98) to ($3.41) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.25 out of 5 starsMedical Sector581st out of 936 stocksPharmaceutical Preparations Industry265th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingXenon Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageXenon Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Xenon Pharmaceuticals' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.33% of the outstanding shares of Xenon Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverXenon Pharmaceuticals has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Xenon Pharmaceuticals has recently increased by 7.21%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldXenon Pharmaceuticals does not currently pay a dividend.Dividend GrowthXenon Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for XENE. Previous Next 4.2 News and Social Media Coverage News SentimentXenon Pharmaceuticals has a news sentiment score of 1.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Xenon Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest2 people have searched for XENE on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Xenon Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Xenon Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.52% of the stock of Xenon Pharmaceuticals is held by insiders.Percentage Held by Institutions95.45% of the stock of Xenon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Xenon Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Xenon Pharmaceuticals are expected to decrease in the coming year, from ($2.98) to ($3.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xenon Pharmaceuticals is -16.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xenon Pharmaceuticals is -16.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXenon Pharmaceuticals has a P/B Ratio of 3.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Xenon Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."Click here now to watch this exclusive interview About Xenon Pharmaceuticals Stock (NASDAQ:XENE)Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.Read More XENE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XENE Stock News HeadlinesJuly 25 at 1:19 AM | americanbankingnews.comStock Traders Buy High Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE)June 27, 2024 | insidermonkey.comIs Xenon Pharmaceuticals Inc. (XENE) One of the Best Healthcare Stocks Under $50?July 27, 2024 | Crypto 101 Media (Ad)Next opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has led to a massive bull run in the year after it happens. That means we're in the "golden window" right now…June 5, 2024 | globenewswire.comXenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceMay 29, 2024 | finance.yahoo.comShareholders Will Probably Not Have Any Issues With Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) CEO CompensationMay 29, 2024 | ca.finance.yahoo.comStocks in play: Satellos Bioscience Inc.May 28, 2024 | globenewswire.comXenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual MeetingMay 27, 2024 | finance.yahoo.comHedge Funds are Racking Up Shares of This Healthcare StockJuly 27, 2024 | Crypto 101 Media (Ad)Next opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has led to a massive bull run in the year after it happens. That means we're in the "golden window" right now…May 13, 2024 | markets.businessinsider.comBuy Rating Affirmed: Xenon’s Strategic Advancements in MDD Development and Diversified PipelineMay 10, 2024 | finance.yahoo.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comXenon Pharmaceuticals Inc (XENE) Reports Increased Losses in Q1 2024, Despite Advancements in ...May 10, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Catalyst Pharma (CPRX), Xenon (XENE) and Intellia Therapeutics (NTLA)May 9, 2024 | washingtonpost.comXenon Pharmaceuticals: Q1 Earnings SnapshotMay 9, 2024 | msn.comXENE Stock Earnings: Xenon Pharmaceuticals Beats EPS for Q1 2024May 9, 2024 | globenewswire.comXenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 8, 2024 | globenewswire.comXenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024May 8, 2024 | globenewswire.comPolarean's Xenon MRI to be Featured at Upcoming ATS 2024 ConferenceSee More Headlines Receive XENE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xenon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/27/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:XENE CUSIPN/A CIK1582313 Webwww.xenon-pharma.com Phone(604) 484-3300Fax604-484-3450Employees210Year FoundedN/APrice Target and Rating Average Stock Price Target$59.11 High Stock Price Target$65.00 Low Stock Price Target$50.00 Potential Upside/Downside+34.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-182,390,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-24.35% Return on Assets-23.28% Debt Debt-to-Equity RatioN/A Current Ratio31.82 Quick Ratio31.82 Sales & Book Value Annual Sales$9.43 million Price / Sales351.82 Cash FlowN/A Price / Cash FlowN/A Book Value$14.18 per share Price / Book3.10Miscellaneous Outstanding Shares75,470,000Free Float71,303,000Market Cap$3.32 billion OptionableOptionable Beta1.26 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Ian C. Mortimer C.M.A. (Age 48)CPA, M.B.A., President, CEO & Director Comp: $973.76kMs. Sherry Aulin (Age 40)Chief Financial Officer Comp: $3.03MMs. Andrea DiFabio J.D. (Age 56)Chief Legal Officer & Corporate Secretary Comp: $200.51kDr. Christopher E. Von Seggern M.B.A. (Age 45)M.P.H., M.P.H. M.B.A, Ph.D., Chief Commercial Officer Comp: $618.07kDr. Christopher John Kenney M.D. (Age 53)Chief Medical Officer Comp: $684.22kMs. Shelley McCloskey B.A. (Age 64)Executive Vice President of Human Resources Dr. Robin P. Sherrington Ph.D. (Age 63)Executive Vice President of Strategy & Innovation Comp: $351.67kDr. James R. Empfield Ph.D. (Age 63)Executive Vice President of Drug Discovery Comp: $323.43kMs. Sheila M. Grant M.B.A.M.Sc., MBA, Executive Vice President of R&D OperationsMore ExecutivesKey CompetitorsSupernus PharmaceuticalsNASDAQ:SUPNSage TherapeuticsNASDAQ:SAGEVoyager TherapeuticsNASDAQ:VYGRMarinus PharmaceuticalsNASDAQ:MRNSCatalentNYSE:CTLTView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpSold 15,656 shares on 7/26/2024Ownership: 0.068%China Universal Asset Management Co. Ltd.Sold 5,652 shares on 7/20/2024Ownership: 0.012%Assenagon Asset Management S.A.Sold 113,004 shares on 7/18/2024Ownership: 0.098%SG Americas Securities LLCBought 5,813 shares on 7/12/2024Ownership: 0.035%Harbor Capital Advisors Inc.Bought 20,891 shares on 7/9/2024Ownership: 0.032%View All Insider TransactionsView All Institutional Transactions XENE Stock Analysis - Frequently Asked Questions How have XENE shares performed this year? Xenon Pharmaceuticals' stock was trading at $46.06 at the beginning of 2024. Since then, XENE stock has decreased by 4.6% and is now trading at $43.96. View the best growth stocks for 2024 here. How were Xenon Pharmaceuticals' earnings last quarter? Xenon Pharmaceuticals Inc. (NASDAQ:XENE) issued its quarterly earnings data on Thursday, May, 9th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.69) by $0.07. Xenon Pharmaceuticals's revenue was up .0% on a year-over-year basis. Who are Xenon Pharmaceuticals' major shareholders? Top institutional investors of Xenon Pharmaceuticals include DNB Asset Management AS (0.23%), Assenagon Asset Management S.A. (0.10%), Bank of New York Mellon Corp (0.07%) and SG Americas Securities LLC (0.03%). Insiders that own company stock include Dawn Svoronos, Ian Mortimer, Gary Patou, James R Empfield, Sherrington Robin, Simon N Pimstone, Christopher John Kenney and Seggern Christopher Von. View institutional ownership trends. How do I buy shares of Xenon Pharmaceuticals? Shares of XENE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Xenon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Xenon Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Corbus Pharmaceuticals (CRBP), Nektar Therapeutics (NKTR), TG Therapeutics (TGTX), Viking Therapeutics (vktx) and Sangamo Therapeutics (SGMO). This page (NASDAQ:XENE) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenon Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xenon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
